Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Gou, Hong Feng ^a   Huang, Juan ^a   Shi, Hua Shan ^a   Chen, Xin Chuan ^a   Wang, Yong Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7; OXALIPLATIN;

ABDOMEN METASTASIS; ABDOMINAL CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE SUBPOPULATION; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84907597892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085789     Document Type: Article

References (45)

1. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, et al. (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491.
2. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543. (Pubitemid 43011261)
3. Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, et al. (2011) Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 60: 341-349.
4. Hernandez-Alcoceba R, Berraondo P (2012) Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. Oncoimmunology 1: 97-99.
5. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, et al. (2001) A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983-2990.
6. Aspinall R, Henson S, Pido-Lopez J, Ngom PT (2004) Interleukin-7: an interleukin for rejuvenating the immune system. Ann N Y Acad Sci 1019: 116-122. (Pubitemid 38951294)
7. Freitas AA, Rocha BB (1993) Lymphocyte lifespans: homeostasis, selection and competition. Immunol Today 14: 25-29. (Pubitemid 23028247)
8. Fry TJ, Mackall CL (2002) Interleukin-7: from bench to clinic. Blood 99: 3892-3904. (Pubitemid 35332024)
9. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, et al. (2005) Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16: 513-533. (Pubitemid 41022015)
10. Mazzucchelli R, Durum SK (2007) Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7: 144-154. (Pubitemid 46178275)
11. Overwijk WW, Schluns KS (2009) Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 132: 153-165.
12. Sin JI, Kim J, Pachuk C, Weiner DB (2000) Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol 7: 751-758.
13. Jicha DL, Mule JJ, Rosenberg SA (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 174: 1511-1515.
14. Kos FJ, Mullbacher A (1993) IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J Immunol 150: 387-393. (Pubitemid 23133613)
15. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, et al. (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci U S A 89: 3850-3854.
16. Hock H, Dorsch M, Diamantstein T, Blankenstein T (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174: 1291-1298.
17. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, et al. (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182: 6951-6958.
18. Lai L, Jin J, Goldschneider I (2011) In vivo antitumor activity of a recombinant IL-7/HGFbeta hybrid cytokine in mice. Cancer Res 71: 61-67.
19. Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, et al. (2003) Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther 14: 1511-1524. (Pubitemid 37357739)
20. Li B, VanRoey MJ, Jooss K (2007) Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 123: 155-165. (Pubitemid 46590070)
21. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, et al. (2009) Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 15: 528-536.
22. Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25: 5426-5434. (Pubitemid 350232219)
23. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, et al. (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20: 1600-1607. (Pubitemid 34260541)
24. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405.
25. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701. (Pubitemid 41815875)
26. Chen G, Emens LA (2013) Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 62: 203-216.
27. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, et al. (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555-1559. (Pubitemid 36373643)
28. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, et al. (1997) Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74: 433-437. (Pubitemid 27400164)
29. Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, et al. (2010) Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5: e10105.
30. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4: 941-952.
31. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, et al. (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67: 425; author reply 426.
32. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166. (Pubitemid 46718400)
33. Mehrotra PT, Grant AJ, Siegel JP (1995) Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol 154: 5093-5102.
34. Liu S, Lizee G, Lou Y, Liu C, Overwijk WW, et al. (2007) IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol 19: 1213-1221. (Pubitemid 47500644)
35. Dubinett SM, Huang M, Dhanani S, Wang J, Beroiza T (1993) Down-regulation of macrophage transforming growth factor-beta messenger RNA expression by IL-7. J Immunol 151: 6670-6680. (Pubitemid 24001041)
36. Miller AR, McBride WH, Dubinett SM, Dougherty GJ, Thacker JD, et al. (1993) Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood 82: 3686-3694. (Pubitemid 24006051)
37. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, et al. (2002) IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest 109: 931-937.
38. Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, et al. (1993) Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest 92: 1918-1924. (Pubitemid 23304561)
39. Kilinc MO, Rowswell-Turner RB, Gu T, Virtuoso LP, Egilmez NK (2009) Activated CD8 + T-effector/memory cells eliminate CD4 + CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol 183: 7656-7660.
40. Le Saout C, Mennechet S, Taylor N, Hernandez J (2008) Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc Natl Acad Sci U S A 105: 19414-19419.
41. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, et al. (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205: 1701-1714. (Pubitemid 351962032)
42. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, et al. (2006) IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29: 313-319. (Pubitemid 44297299)
43. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, et al. (1998) Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 77: 1907-1916.
44. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, et al. (2009) Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119: 997-1007.
45. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, et al. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113: 6304-6314.